Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Joseph Rimando, Francesco Mazziotta, Alison Gareau, Maria Bettinotti, Jonathan Allen Webster, Syed Abbas Ali, Philip Imus, Mario Victor Lemas, Amy E. DeZern, Mark J. Levis, Marianna Zahurak, Ravi Varadhan, Richard F. Ambinder, Carol Huff, Ivana Gojo, Richard J. Jones, Ivan M. Borrello, Leo Luznik

Blood (2023) 142 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2023-179394

Published: 2023

Journal Articles

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Amy E. DeZern, Marianna Zahurak, Heather J. Symons, Kenneth R. Cooke, Carol Ann Huff, Tania Jain, Lode J. Swinnen, Philip H. Imus, Nina D. Wagner-Johnston, Richard F. Ambinder, Mark Levis, Leo Luznik, Javier Bolaños-Meade, Ephraim J. Fuchs, Richard J. Jones, Robert A. Brodsky

Blood (2023) 141 (25): 3031–3038.

https://doi.org/10.1182/blood.2023020435

Published: 2023

Includes: Supplemental data

Journal Articles

Alternative Bone Marrow Transplantation with Post-Transplant Cyclophosphamide (PTCy) As Initial Therapy for Acquired Severe Aplastic Anemia (SAA)

Amy E. DeZern, Marianna Zahurak, Kenneth R. Cooke, Richard J. Jones, Robert Brodsky

Blood (2022) 140 (Supplement 1): 4868–4869.

https://doi.org/10.1182/blood-2022-157861

Published: 2022

Journal Articles

The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA)

Amy E. DeZern, MD, Marianna Zahurak, MS, Kenneth R. Cooke, MD, David Margolis, MD, Richard J. Jones, MD, Robert A. Brodsky, MD

Blood (2019) 134 (Supplement_1): 147.

https://doi.org/10.1182/blood-2019-121900

Published: 2019

Journal Articles

Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tolerable Rates of Graft-Vs-Host Disease (GVHD)

Amy E. DeZern, MD, Marianna Zahurak, MS, Javier Bolanos-Meade, MD, Richard J. Jones, MD

Blood (2019) 134 (Supplement_1): 3320.

https://doi.org/10.1182/blood-2019-122762

Published: 2019

Journal Articles

Nonmyeloablative (NMA), HLA-Haploidentical (Haplo) Blood or Marrow Transplantation (BMT) from Non-First-Degree Related Donors Has Similar Outcomes to First-Degree Related BMT

Hany Elmariah, MDMS, Yvette L Kasamon, MD, Marianna Zahurak, MS, Noah Tucker, CCRC, Gary Rosner, ScD, F Javier Bolanos-Meade, MD, Ravi Varadhan, PhD, Ephraim J. Fuchs, MD MBA, Amy E. DeZern, MD, Leo Luznik, MD, Richard J. Jones, PhD, Richard F Ambinder, MD

Blood (2017) 130 (Supplement 1): 3304.

https://doi.org/10.1182/blood.V130.Suppl_1.3304.3304

Published: 2017

Journal Articles

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Blood (2017) 129 (10): 1389–1393.

https://doi.org/10.1182/blood-2016-09-737825

Published: 2017

Includes: Supplemental data

Journal Articles

Shortened-Duration Tacrolimus after Nonmyeloablative HLA-Haploidentical (NMA haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Facilitates Strategies for Relapse Reduction

Yvette L. Kasamon, Ephraim J. Fuchs, MD, Marianna Zahurak, Gary L. Rosner, Heather J. Symons, Javier Bolaños-Meade, Richard J. Jones

Blood (2016) 128 (22): 831.

https://doi.org/10.1182/blood.V128.22.831.831

Published: 2016

Journal Articles

Nonmyeloablative (NMA), HLA-Mismatched Unrelated Donor (mMUD) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Has Outcomes Similar to Matched BMT

Yvette L. Kasamon, Ephraim J. Fuchs, Javier Bolaños-Meade, Mary S. Leffell, Marianna Zahurak, Gary L. Rosner, Jonathan D. Powell, Richard F. Ambinder, Richard J. Jones, Leo Luznik

Blood (2015) 126 (23): 2002.

https://doi.org/10.1182/blood.V126.23.2002.2002

Published: 2015

Journal Articles

Addition Of Clarithromycin To Lenalidomide and Dexamethasone (BiRd) Is Effective In Multiple Myeloma After Progression On Lenalidomide and Dexamethasone

Nilanjan Ghosh, MD, PhD, Noah Tucker, Marianna Zahurak, M.S., Jocelyn L. Wozney, MD, Ivan M. Borrello, MD, Carol Ann Huff, M.D.

Blood (2013) 122 (21): 1960.

https://doi.org/10.1182/blood.V122.21.1960.1960

Published: 2013

Journal Articles

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Heather Symons, MD, MHS, Allen R. Chen, MD, PhD, MHS, M. Sue Leffell, PhD, Marianna Zahurak, M.S., Kathy Schultz, Heather Karaszkiewicz, Leo Luznik, MD, Javier Bolanos Meade, MD, Yvette L. Kasamon, MD, Lode J. Swinnen, MD, Douglas Edward Gladstone, MD, Richard J. Jones, MD, Ephraim Fuchs, MD, MBA

Blood (2010) 116 (21): 2362.

https://doi.org/10.1182/blood.V116.21.2362.2362

Published: 2010

Journal Articles

Defining An Optimal Therapeutic Range for Busulfan (Bu) Administered with Pre-and Post-Transplant Cyclophosphamide (Cy) In HLA-Matched Related and Unrelated Bone Marrow Transplantation (BMT).

Lindsey R Lombardi, PharmD, Marianna Zahurak, M.S., Nadira Durakovic, MD, PhD, Jeanne Kowalski, PhD, Richard J. Jones, MD, Leo Luznik, MD

Blood (2010) 116 (21): 3474.

https://doi.org/10.1182/blood.V116.21.3474.3474

Published: 2010

Journal Articles

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

Leo Luznik, Javier Bolaños-Meade, Marianna Zahurak, Allen R. Chen, B. Douglas Smith, Robert Brodsky, Carol Ann Huff, Ivan Borrello, William Matsui, Jonathan D. Powell, Yvette Kasamon, Steven N. Goodman, Allan Hess, Hyam I. Levitsky, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs

Blood (2010) 115 (16): 3224–3230.

https://doi.org/10.1182/blood-2009-11-251595

Published: 2010

NARROW

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Alternative Bone Marrow Transplantation with Post-Transplant Cyclophosphamide (PTCy) As Initial Therapy for Acquired Severe Aplastic Anemia (SAA)

The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA)

Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tolerable Rates of Graft-Vs-Host Disease (GVHD)

Nonmyeloablative (NMA), HLA-Haploidentical (Haplo) Blood or Marrow Transplantation (BMT) from Non-First-Degree Related Donors Has Similar Outcomes to First-Degree Related BMT

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Shortened-Duration Tacrolimus after Nonmyeloablative HLA-Haploidentical (NMA haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Facilitates Strategies for Relapse Reduction

Nonmyeloablative (NMA), HLA-Mismatched Unrelated Donor (mMUD) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Has Outcomes Similar to Matched BMT

Addition Of Clarithromycin To Lenalidomide and Dexamethasone (BiRd) Is Effective In Multiple Myeloma After Progression On Lenalidomide and Dexamethasone

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Defining An Optimal Therapeutic Range for Busulfan (Bu) Administered with Pre-and Post-Transplant Cyclophosphamide (Cy) In HLA-Matched Related and Unrelated Bone Marrow Transplantation (BMT).

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only